Cytotoxicity of sulfonamide reactive metabolites:: apoptosis and selective toxicity of CD8+ cells by the hydroxylamine of sulfamethoxazole

被引:50
作者
Hess, DA
Sisson, ME
Suria, H
Wijsman, J
Puvanesasingham, R
Madrenas, J
Reider, MJ
机构
[1] Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pediat, John P Robarts Res Inst,Gene Therapy & Mol Virol, London, ON N6J 1Y5, Canada
[2] Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pharmacol & Toxicol, John P Robarts Res Inst,Gene Therapy & Mol Virol, London, ON N6J 1Y5, Canada
[3] Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON, Canada
[4] Univ Western Ontario, John P Robarts Res Inst, Transplantat & Immunobiol Grp, Dept Med, London, ON, Canada
[5] Univ Western Ontario, John P Robarts Res Inst, Transplantat & Immunobiol Grp, Dept Immunol & Microbiol, London, ON, Canada
关键词
cytochrome P450; MACS; apoptosis; cell viability;
D O I
10.1096/fasebj.13.13.1688
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Treatment with sulfonamide antibiotics in HIV-infected patients is associated with a high incidence (> 40%) of adverse drug events, including severe hypersensitivity reactions. Sulfonamide reactive metabolites have been implicated in the pathogenesis of these adverse reactions, Sulfamethoxazole hydroxylamine (SMX-HA) induces lymphocyte toxicity and suppression of proliferation in vitro; the mechanism(s) of these immunomodulatory effects remain unknown, We investigated the cytotoxicity of SMX-HA via apoptosis on human peripheral blood mononuclear cells and purified cell subpopulations in vitro. CD19(+), CD4(+), and CD8(+) cells were isolated from human peripheral blood by positive selection of cell surface molecules by magnetic bead separation. SMX-HA induced significant CD8(+) cell death (67 +/- 7%) at 100 mu M SMX-HA, with only minimal CD4(+) cell death (8 +/- 4%). No significant subpopulation toxicity was shown when incubated with parent drug (SMX). Flow cytometry measuring phosphatidylserine externalization 24 h after treatment with 100 mu M and 400 mu M SMX-HA revealed 14.1 +/- 0.7% and 25.6 +/- 4.2% annexin-positive cells, respectively, compared to 3.7 +/- 1.2% in control PBMCs treated with 400 mu M SMX. Internucleosomal DNA fragmentation was observed in quiescent and stimulated PBMCs 48 h after incubation with SMX-HA. Our data show that CD8(+) cells are highly susceptible to the toxic effects of SMX-HA through enhanced cell death by apoptosis.-Hess, D. A., Sisson, M. E., Suria, H., Wijsman, J., Puvanesasingham, R., Madrenas, J., Rieder, M. J. Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole.
引用
收藏
页码:1688 / 1698
页数:11
相关论文
共 74 条
[1]   The costs of adverse drug events in hospitalized patients [J].
Bates, DW ;
Spell, N ;
Cullen, DJ ;
Burdick, E ;
Laird, N ;
Petersen, LA ;
Small, SD ;
Sweitzer, BJ ;
Leape, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :307-311
[2]  
BATTYE FL, 1991, CURR OPIN IMMUNOL, V3, P238
[3]   A URINARY METABOLITE RATIO THAT REFLECTS SYSTEMIC CAFFEINE CLEARANCE [J].
CAMPBELL, ME ;
SPIELBERG, SP ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :157-165
[4]  
CARR A, 1993, CLIN EXP IMMUNOL, V94, P21
[5]   CLINICAL AND LABORATORY MARKERS OF HYPERSENSITIVITY TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN PATIENTS WITH PNEUMOCYSTIS-CARINII PNEUMONIA AND AIDS [J].
CARR, A ;
SWANSON, C ;
PENNY, R ;
COOPER, DA .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (01) :180-185
[6]   ACETYLATION PHENOTYPE AND CUTANEOUS HYPERSENSITIVITY TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HIV-INFECTED PATIENTS [J].
CARR, A ;
GROSS, AS ;
HOSKINS, JM ;
PENNY, R ;
COOPER, DA .
AIDS, 1994, 8 (03) :333-337
[7]  
CARR A, 1993, J ACQ IMMUN DEF SYND, V6, pS56
[8]   ALLERGIC MANIFESTATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION [J].
CARR, A ;
COOPER, DA ;
PENNY, R .
JOURNAL OF CLINICAL IMMUNOLOGY, 1991, 11 (02) :55-64
[9]  
Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457
[10]   Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality [J].
Classen, DC ;
Pestotnik, SL ;
Evans, RS ;
Lloyd, JF ;
Burke, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :301-306